

# PULMONARY ANTIHYPERTENSIVES PRIOR AUTHORIZATION REQUEST FORM



**OptumRx**  
 P.O. Box 25184  
 Santa Ana, CA, 92799  
 Phone: (800) 310-6826 Fax: (866) 940-7328



/  /

**Note: This form must be completed by the prescribing provider.**

**\*\*All sections must be completed or the request will be returned\*\***

Patient's Medicaid # <input type="text"/>	Date of Birth <input type="text"/> / <input type="text"/> / <input type="text"/>
Patient's Name	Prescriber's Name
Prescriber's IN License # <input type="text"/>	Specialty
Prescriber's NPI # <input type="text"/>	Prescriber's Signature
Return Fax # <input type="text"/> - <input type="text"/> - <input type="text"/>	Return Phone # <input type="text"/> - <input type="text"/> - <input type="text"/>
Check box if requesting retro-active PA <input type="checkbox"/>	Date(s) of service requested for retro-active eligibility (if applicable):

*Note: Submit PA requests for retroactive claims (dates of service prior to eligibility determination, but within established eligibility timelines) with dates of service prior to 30 calendar days of submission separately from current PA requests (dates of service 30 calendar days or less and going forward).*

Requested Medication	Strength	Quantity	Dosage Regimen

**General information applicable to all products:**

<p><b>Pulmonary Antihypertensive PA Requirements for ALL agents:</b></p> <p>1. Member has a diagnosis of pulmonary arterial hypertension <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>2. Member has a diagnosis of pulmonary hypertension associated with interstitial lung disease (only applicable to Tyvaso/Tyvaso DPI) <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>3. Member has a diagnosis of chronic thromboembolic pulmonary hypertension (CTEPH) (only applicable to Adempas) <input type="checkbox"/> Yes <input type="checkbox"/> No</p> <p>4. Requested agent has been prescribed by, or in consultation with, a pulmonologist or cardiologist <input type="checkbox"/> Yes <input type="checkbox"/> No</p>
--

**Product specific information:**

**If the request is for Adempas (riociguat):**

1. For those of childbearing potential, a negative pregnancy test obtained in the past 30 days has been submitted  Yes  No  Not applicable to member  
Date of negative pregnancy test (include documentation): \_\_\_\_\_
2. Member is currently receiving one of the following: nitrate therapy, PDE5 inhibitor, nonspecific PDE inhibitor (dipyridamole; theophylline; aminophylline), vericiguat  Yes  No
3. Member is enrolled in the riociguat REMS program if meeting eligibility requirement  
 Yes  No  Not applicable to member
4. Dose requested is 7.5mg per day or less  Yes  No  
If no, please explain: \_\_\_\_\_

**If the request is for Adcirca (tadalafil):**

1. Member is currently receiving one of the following: nitrate therapy, PDE-5 inhibitor (other than the one being requested), riociguat  Yes  No
2. Dose requested is 40 mg per day or less  Yes  No

**Note: 'Alyq' requires trial and failure of generic tadalafil or medical justification for use**

**If the request is for Letairis (ambrisentan):**

1. Member is enrolled in the ambrisentan or PS-ambrisentan REMS program if meeting eligibility requirement  Yes  No  Not applicable to member
2. For those of childbearing potential, a negative pregnancy test obtained in the past 30 days has been submitted  Yes  No  Not applicable to member  
Date of negative pregnancy test (include documentation): \_\_\_\_\_
3. Member is currently receiving cyclosporine therapy (requires dose reduction)  Yes  No  
**Note: dose of Letairis (ambrisentan) must be adjusted to max: 5 mg/day**
4. Member has had a previous trial and failure of Tracleer (bosentan)  Yes  No  
If no, please explain \_\_\_\_\_
5. Dose requested is 10 mg per day or less  Yes  No

**If the request is for Liqrev (sildenafil) oral suspension:**

1. Member is 18 years of age or older  Yes  No
2. Member is unable to swallow tablet formulation  Yes  No
3. Member is currently receiving one of the following: nitrate therapy, riociguat, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir, tipranavir, PDE-5 inhibitor (other than the one being requested)  Yes  No
4. Dose requested is 60 mg per day or less  Yes  No
5. Member has had a previous trial and failure of sildenafil suspension  Yes  No  
If no, please explain \_\_\_\_\_

**If the request is for Opsumit (macitentan):**

1. Member is enrolled in the macitentan REMS program if meeting eligibility requirement  
 Yes  No  Not applicable to member
2. For those of childbearing potential, a negative pregnancy test obtained in the past 30 days has been submitted  Yes  No  Not applicable to member  
Date of negative pregnancy test (include documentation): \_\_\_\_\_
3. Member has had a previous trial and failure of Tracleer (bosentan)  Yes  No  
If no, please explain \_\_\_\_\_
4. Dose requested is 10 mg per day or less  Yes  No

**If the request is for Opsynvi (macitentan/tadalafil):**

1. Member is enrolled in the macitentan/tadalafil REMS program if meeting eligibility requirement  
 Yes  No  Not applicable to member
2. For those of childbearing potential, a negative pregnancy test obtained in the past 30 days has been submitted  Yes  No  Not applicable to member  
Date of negative pregnancy test (include documentation): \_\_\_\_\_
3. Member has had a previous trial and failure of separate components (macitentan & tadalafil)  
 Yes  No  
If no, please explain \_\_\_\_\_
4. Member is currently receiving one of the following: nitrate therapy, PDE-5 inhibitor (other than the one being requested), riociguat  Yes  No
5. Dose requested is 10 mg/40 mg per day or less  Yes  No

**If the request is for Orenitram (treprostiril):**

1. Does the member have severe hepatic impairment (Child-Pugh class C)?  Yes  No  
**Note: members with Child-Pugh class C hepatic impairment will be denied; Orenitram titration packs will be limited to 1 pack per 90 days**

**If the request is for Revatio (sildenafil) tablets or injection:**

1. Member is currently receiving one of the following: nitrate therapy, riociguat, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir, tipranavir, PDE-5 inhibitor (other than the one being requested)  Yes  No
2. Dose requested is 60 mg per day or less  Yes  No

**If the request is for Revatio (sildenafil) oral suspension:**

1. Member is under 12 years of age  Yes  No
2. Member is unable to swallow tablet formulation  Yes  No
3. Member is currently receiving one of the following: nitrate therapy, riociguat, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir/ritonavir, nelfinavir, ritonavir, saquinavir, tipranavir, PDE-5 inhibitor (other than the one being requested)  Yes  No
4. Dose requested is 60 mg per day or less  Yes  No

**If the request is for Tadliq (tadalafil) oral suspension:**

1. Member is under 12 years of age  Yes  No
2. Member is unable to swallow tablet formulation  Yes  No
3. Member is currently receiving one of the following: nitrate therapy, PDE-5 inhibitor (other than the one being requested), riociguat  Yes  No
4. Dose requested is 40 mg per day or less  Yes  No
5. Member has had a previous trial and failure of sildenafil oral suspension  Yes  No  
If no, please explain \_\_\_\_\_

**If the request is for Uptravi (selexipag):**

1. Member has had a previous trial and failure of Orenitram (treprostinil)  Yes  No  
If no, please explain \_\_\_\_\_
2. Will the member be utilizing a CYP2C8 inhibitor (e.g., gemfibrozil) concurrently with selexipag?  
 Yes  No  
**Note: members planning to use CYP2C8 inhibitors concurrently with selexipag will be denied**

**If the request is for Tracleer (bosentan):**

Request is for:

- Tracleer tablet
  - Tracleer dispersible tablet
  - bosentan tablet\*
1. Member is enrolled in the bosentan REMS program (**Note: ALL members must be enrolled in the bosentan REMS program**)  Yes  No
  2. For those of childbearing potential, a negative pregnancy test obtained in the past 30 days has been submitted  Yes  No  Not applicable to member  
Date of negative pregnancy test (include documentation): \_\_\_\_\_
  3. Will the member be utilizing cyclosporine-A or glyburide therapy concurrently with bosentan?  
 Yes  No  
**Note: members planning to use cyclosporine-A or glyburide concurrently with bosentan will be denied**
  4. Member age: \_\_\_\_\_ weight: \_\_\_\_\_ LB/KG (circle one)
  5. Does the requested dose exceed 250mg per day OR dose limits based on age/weight listed in criteria?  Yes  No  
If yes, please explain: \_\_\_\_\_

**If the request is for Winrevair (sotarcept-csrk)**

1. Member is 18 years of age or older  Yes  No
2. Member has had a previous trial and failure of at least 60 days of therapy with any agent from TWO of the following subcategories: endothelin receptor antagonists, phosphodiesterase 5-inhibitors, prostacyclin receptor modulators, or soluble guanylate cyclase inhibitor  Yes  No

If yes, please list each agent and dates of trial (start and stop dates, if therapy is ongoing indicate as such):

- Endothelin receptor antagonist:
  - Medication name: \_\_\_\_\_
  - Dates of trial: \_\_\_\_\_
- Phosphodiesterase 5-inhibitor:
  - Medication name: \_\_\_\_\_
  - Dates of trial: \_\_\_\_\_
- Prostacyclin receptor modulator:
  - Medication name: \_\_\_\_\_
  - Dates of trial: \_\_\_\_\_
- Soluble guanylate cyclase inhibitor:
  - Medication name: \_\_\_\_\_
  - Dates of trial: \_\_\_\_\_

If no, please explain \_\_\_\_\_

3. Member's actual body weight: \_\_\_\_\_ LB/KG (circle one)
- a. Does the requested dose exceed 0.7 mg/kg every 3 weeks?  Yes  No
- If yes, please explain:  
\_\_\_\_\_

4. Prescriber attests to all of the following:
- a. Prescriber has obtained baseline hemoglobin and platelet count prior to initiating therapy  
 Yes  No
- b. Baseline platelet count is 50,000/mm<sup>3</sup> (50 x 10<sup>6</sup>/L) or greater  Yes  No
- c. Prescriber will continue to monitor hemoglobin and platelet count and adjust dosing per the prescribing information  Yes  No

**CONFIDENTIAL INFORMATION**

This facsimile transmission (and attachments) may contain protected health information from the Indiana Health Coverage Programs (IHCP), which is intended only for the use of the individual or entity named in this transmission sheet. Any unintended recipient is hereby notified that the information is privileged and confidential, and any use, disclosure, or reproduction of this information is prohibited.